A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
Clinical trial NCT07661173 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07661173
- Sponsor
- Anhui Provincial Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-06
- Primary completion
- 2029-03-06
- Enrollment
- 154
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.